drugset / Trial / NCT00450320
Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
Phase 1
Completed
7 enrolled
AIDS Malignancy Consortium
National Cancer Institute (NCI) · collabThe Emmes Company, LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sirolimus also may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This pilot study is studying sirolimus in treating patients with HIV-related Kaposi's sarcoma.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sirolimus | Small molecule | 0.0015 mg/kg | Oral |
| Comparator | Sirolimus | Small molecule | 0.003 mg/kg | Oral |
| Comparator | Sirolimus | Small molecule | 0.05 mg/kg | Oral |